Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07257068 · ClinicalTrials.gov registry record · NA
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
A NA study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT07257068: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT07257068 is a NA study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07257068, a NA study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Interventions
- OTHER Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-09-14 |
| Est. Completion | 2029-12-31 |
| Phase | NA |
What is known before NCT07257068 opens enrollment
NCT07257068 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Infliximab is the first listed.
NCT07257068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07257068 about?
NCT07257068 is a clinical study titled "Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study". To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
What is the current status of trial NCT07257068?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 14 participants. The study started on 2026-09-14. Estimated completion is 2029-12-31.
What interventions are being tested in trial NCT07257068?
The interventions under investigation include: Infliximab (OTHER).
Who is sponsoring clinical trial NCT07257068?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07257068's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy